JAK Attack: Ajax Takes Aim at Myelofibrosis
Drug development based on Janus kinase (JAK) inhibitors hasn’t progressed as far as other biopharma specialties since the first such treatment won approval more than a decade ago. Ajax Therapeutics, a drug developer created to develop JAK inhibitors for …